News

Certara will enhance its physiologically-based pharmacokinetic (PBPK) modeling and simulation platform to assess the bioequivalence of drugs absorbed through the skin, while also factoring in variability in specific

The company is closely collaborating with the World Health Organization (WHO), the National Institute of Allergy and Infectious Diseases (NIAID), as well as other key stakeholders, governments, and

The company will assess the safety, tolerability, and pharmacokinetics of TNX-201 in a healthy volunteers trial scheduled to be completed before the end of 2014. IMH has a

The double-blind, randomized, placebo-controlled LUME-COLON 1 trial will evaluate the efficacy and safety of nintedanib plus best supportive care (BSC), versus placebo plus BSC, after previous treatment with

While the current focus of the Company’s PolyStart technology is on TapImmune’s cancer program (e.g., Her2/neu and folate receptor alpha antigens), the Company none-the-less strongly reaffirms that this

Apart from the EMA orphan designation status, the company has also received fast track designation by the US Food and Drug Administration (FDA) for Epidiolex to treat Dravet

This expanded program will combine the strength of the iBioLaunch platform with Novici’s patented GRAMMR technology for rapid evolution of gene sequences to significantly increase expression yield of

This new agreement follows the December 2012 collaboration between the two companies and focuses on the field of immuno-oncology, while further broadening the Sutro platform for discovery, development,

Melanoma can be caused by abnormal changes or mutations in a cell protein called BRAF V600. The drug is recommended for people whose melanoma has spread or cannot